India, Feb. 6 -- While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2025.
For fiscal 2025, the company now projects adjusted earnings in a range of $6.55 to $6.85 per share on worldwide total revenues of about $45.5 billion.
On average, 25 analysts polled expect the company to report earnings of $6.92 per share on a revenues decline of 2.59 percent to $46.27 billion for the year. Analysts' estimates typically exclude special items.
The outlook reflects the near-term impact of generics across Revlimid, Pomalyst, Sprycel and Abraxane, which is expected to result in a revenue decline of approximately 18 to 20 perce...